Skip to content
Senores Pharmaceuticals logo

Senores Pharmaceuticals

SENORES NSE
₹1,137.00 No trade today
P/E
41.45
View as Markdown
MCP
Close 4 Nov 2026 ₹1,137.00 +332.15 +41.3% 1Y
Start ₹804.85

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
15.10%
Debt to Equity
0.37
EPS (TTM)
₹27.43
Book Value
₹217.79
Market Cap
—
P/E (TTM)
41.45
P/B
5.22
ROE
13.40%
Dividend Yield
0.00%
EBITDA
₹168 Cr
52W High
₹1,599.00
52W Low
₹706.00
Volume
0

Peer Comparison

Healthcare › Pharmaceuticals

Senores Pharmaceuticals peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Senores Pharmaceuticals (this company)
₹1,137.0041.45₹5,250 Cr5.220.00%13.40%15.10%₹688 Cr₹131 Cr
Median 8 companies₹1,587.7040.13₹1,25,337 Cr4.990.44%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

49 Average

Data confidence 98/100

Category scores

Quality
42
Weak
Returns, margins, earnings quality 22% weight
Valuation
36
Poor
Cheap vs sector & own history 24% weight
Growth
97
Strong
Sales & profit trajectory 9% weight
Financial Health
29
Poor
Solvency, leverage, coverage 9% weight
Momentum
42
Weak
Trend strength, vol-adjusted 12% weight
Ownership
53
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

6
  • Stock is trading at 6.03 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 13.9% over last 3 years.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 187 days.
  • Working capital days have increased from 67.9 days to 132 days

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1162
OscillatorsBearish261
Moving AveragesStrong Bearish901

Key readings

RSI (14)
35.28
Neutral
MACD (12,26,9)
−57.39
Bearish
SMA (50)
1,355.86
Bearish
SMA (200)
1,118.91
Bullish

As of

Analyst Rating

Based on 5 analysts
BUY100%

5 of 5 analysts rate Buy, 0 Hold, 0 Sell.

As of

BUY
5
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
3Y+162.49%
1Y+59.05%
TTM+50.88%

Net profit

Net profit growth by window
3Y+147.98%
1Y+110.34%
TTM+92.65%

Operating cash flow

Operating cash flow growth by window
3YTurned positive
1YTurned positive
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
3Y−10.60 pp
1Y+3.93 pp
TTM+6.85 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2022₹14.00 Cr
Mar 2023₹35.00 Cr
Mar 2024₹215 Cr
Mar 2025₹398 Cr
Mar 2026₹633 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2022₹1.00 Cr
Mar 2023₹8.00 Cr
Mar 2024₹33.00 Cr
Mar 2025₹58.00 Cr
Mar 2026₹122 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹271 Cr +25.6% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk high

Senores Pharmaceuticals trades at a market cap of ₹6,358 Cr with a PE of 52.3x and has delivered exceptional top-line growth of 162% CAGR over 3 years, but carries concerns around working capital efficiency with debtor days at 187 and no dividend payouts despite consistent profitability.

Bull Case 7
  • Compounded sales growth of 162% CAGR over 3 years indicates rapid revenue scale-up in the pharmaceutical space
  • TTM sales growth of 59% demonstrates continued strong momentum even on a larger base
  • Compounded profit growth of 139% CAGR over 3 years outpaces many pharma peers significantly
  • TTM profit growth of 97% shows accelerating bottom-line expansion year-over-year
  • Stock has delivered 144% returns over 1 year reflecting strong market confidence in the business trajectory
  • Company is expected to deliver a good upcoming quarter based on operational momentum
  • Consistent ROE of 13-14% over the last 3 years indicates stable profitability despite rapid growth phase
Bear Case 7
  • Debtor days at 187 days is extremely high, indicating potential collection challenges or channel-stuffing risk
  • Working capital days have deteriorated sharply from 67.9 days to 132 days, straining cash flows
  • Price-to-book of 6.81x is elevated for a company with ROE of only 13.9%, implying premium valuation not fully justified by returns
  • Zero dividend yield despite reporting repeated profits suggests cash is being retained without clear capital allocation policy
  • ROE of 13.9% over 3 years is below the 15-20% threshold typically expected for quality pharma compounders
  • Possible capitalization of interest costs may be flattering reported profitability relative to true operating performance
  • Limited long-term track record with no available 5-year or 10-year growth data makes durability of growth difficult to assess

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: Senores Pharmaceuticals is in a governance-heavy phase with no operational positives reported. The proposed variation of ₹650.16 million in IPO proceeds and ₹754 crore in related party transactions warrant investor scrutiny on capital discipline. The departure of the Company Secretary adds mild uncertainty. The near-term outlook depends on shareholder approval outcomes by August 3 and clarity on how redirected funds will be deployed.

Headwinds 3
  • IPO proceeds utilisation change sought Jul 4

    Company seeks shareholder approval to vary utilisation of ₹650.16 million in unutilised IPO proceeds, raising questions about original capital allocation plans.

  • Large related party transactions Jul 4

    Seeking approval for material related party transactions aggregating ₹754 crore and enhanced limits for loans/guarantees under Sections 185 and 186.

  • Company Secretary relieved Jun 10

    CS Vinay Kumar Mishra relieved from duties effective June 10, 2026, with MD and CFO now handling disclosures directly.

Neutral 3
  • Postal ballot voting opens Jul 4

    Voting on IPO proceeds variation and RPT approvals runs from July 5 to August 3, 2026.

  • Analyst meet in Ahmedabad Jul 1

    Group meeting for analysts and investors scheduled for July 7, 2026, in Ahmedabad using publicly available information.

  • Virtual investor conference Jun 9

    Virtual investor conference hosted by Choice Broking held on June 12, 2026, relying on publicly available information.

Quarterly Results

₹ Cr
SENORES quarterly results, ₹ crore
Particulars Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
79
102
80
101
103
114
138
162
171
175
180
192
Expenses
64
80
59
77
77
95
104
112
121
128
126
135
Operating Profit
15
22
21
23
26
19
34
50
50
47
54
58
OPM %
19%
22%
27%
23%
25%
17%
25%
31%
29%
27%
30%
30%
Other Income
1
2
0
2
5
12
3
5
7
18
3
9
Interest
2
3
5
5
6
5
5
6
5
8
7
9
Depreciation
3
4
4
4
4
5
6
8
8
9
10
10
PBT
10
18
13
16
20
21
26
41
45
47
39
48
Tax %
31%
19%
19%
18%
20%
13%
20%
26%
25%
23%
23%
23%
Net Profit
7
14
11
13
16
18
21
30
34
37
30
37
EPS (₹)
2.37
5.23
3.23
3.86
3.73
3.87
4.28
7.03
6.87
6.86
6.67
—

Sep 2026: from the results filed on 29 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
SENORES profit and loss, annual, ₹ crore
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
14
35
215
398
633
688
Expenses
12
23
173
309
464
487
Operating Profit
2
13
42
90
168
201
OPM %
14%
36%
19%
23%
27%
29%
Other Income
0
4
3
19
47
33
Interest
1
2
9
22
25
27
Depreciation
1
2
10
17
31
35
PBT
1
12
25
71
159
172
Tax %
13%
32%
−31%
17%
24%
—
Net Profit
1
8
33
58
122
131
EPS (₹)
1.01
8.59
10.31
12.72
25.05
27.43
Div. Payout %
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
SENORES balance sheet, annual, ₹ crore
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
9
10
31
46
46
Reserves
28
36
174
740
888
Borrowings
15
63
258
315
342
Other Liabilities
8
23
160
126
328
Total Liabilities
59
131
622
1,227
1,604
Fixed Assets
7
27
235
301
755
CWIP
8
34
97
172
17
Investments
15
16
0
0
4
Other Assets
29
53
289
754
827
Total Assets
59
131
622
1,227
1,604

Cash Flow

₹ Cr
SENORES cash flow, annual, ₹ crore
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−10
−1
−26
−46
62
Investing
−24
−48
−54
−429
−121
Financing
36
46
87
573
−1
Net Cash Flow
2
−3
8
98
−60
Free Cash Flow
−21
−48
−78
−203
−203
CFO/EBITDA
−526
3
−56
−41
45

Ratios

SENORES financial ratios, annual
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
506
228
191
114
187
Inventory Days
135
89
184
232
130
Days Payable
324
388
556
275
340
Cash Conversion Cycle
317
−71
−182
70
−24
Working Capital Days
359
−7
−16
88
132
ROCE %
—
18%
12%
11%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Senores Pharmaceuticals insights

67 extracted metrics across FY22–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 45.82%
  • Public 29.39%
  • DIIs 10.84%
  • Others 7.94%
  • FIIs 6.01%

2.81% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Senores Pharmaceuticals

What does Senores Pharmaceuticals Ltd do?
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities
Where is Senores Pharmaceuticals Ltd (SENORES) listed?
Senores Pharmaceuticals Ltd trades as SENORES on the NSE and under code 544319 on the BSE.
Which sector does Senores Pharmaceuticals Ltd belong to?
Senores Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd trades at a PE ratio of 41.45 as of 4 Nov 2026, on earnings per share of ₹27.43, against a book value of ₹217.79 per share.
What is the 52-week high and low of Senores Pharmaceuticals Ltd?
Over the last 52 weeks Senores Pharmaceuticals Ltd has traded between ₹706 and ₹1,599 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd reported a return on equity of 13.40%. Its debt-to-equity ratio is 0.37.

Company Information

Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities

Website senorespharma.com
Listed 30 Dec 2024
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SENORES.md for Senores Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month